Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid

Exclusion Criteria

• •Have a 12-lead ECG abnormality that, in the opinion of the Investigator,
• •* increases the risk associated with participating in the study
• •* may confound ECG data analysis
• •* a QTcF: \>450 millisecond (msec) for males, or \>470 msec for females
• •* short PR interval \<120 msec or PR interval \>220 msec
• •* second or third degree atrioventricular block
• •* intraventricular conduction delay with QRS \>120 msec
• •* complete right bundle branch block
• •* left bundle branch block, or
• •* Wolff Parkinson-White syndrome
• •Have a current or recent acute, active infection (for example, for a least 30 days before screening and up to Day -1, participants must have no symptoms or signs of infection in the absence of any anti-infective treatment).
• •Had any malignancy within the past 5 years. Exceptions: successfully treated basal cell skin carcinoma or squamous cell skin carcinoma, with no evidence of recurrence or metastatic disease within the 3 years prior to baseline.
• •Have inflammatory bowel disease (IBD), including ulcerative colitis or Crohn's disease.